Novel Radionuclide Agent Delivers "Striking" Results in Neuroendocrine Tumors

Anita T. Shaffer @Shaffer1
Published: Tuesday, Aug 02, 2016
Jonathan R. Strosberg

Jonathan R. Strosberg, MD

Lutathera (lutetium Lu 177 dotatate) has demonstrated “quite striking” results with a favorable safety profile as a therapy for patients with progressive midgut neuroendocrine tumors (NETs) in the first randomized phase III study to evaluate a radiolabeled somatostatin analogue in this treatment setting, according to a leading researcher.

Pivotal Trial Details

The NETTER-1 study enrolled patients with inoperable, well-differentiated, somatostatin receptor–positive NETs of the small intestine or distal colon (midgut carcinoid tumors) who had progressed after standard-dose octreotide LAR (30 mg) therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication